CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase 1 Completion

Press release content from Business Wire. The AP news staff was not involved in its creation.

Related Keywords

Spain ,Germany ,Switzerland ,Catalym Gmb ,Phil Lhuillier ,Ignacio Melero Center ,World Health Organization ,International Nonproprietary Name ,Trophic Communications ,Differentiation Factor ,Ignacio Melero ,Advanced Medical Research ,Principal Investigator ,Eugen Leo ,Chief Medical Officer ,Phill Huillier ,Growth Differentiation ,Laura Mittmann ,Catalym Gmbh ,Business Wire ,Business ,Health ,Tumors ,